Revelation Biosciences (REVB) director awarded 41,981 restricted units

Rhea-AI Filing Summary

Revelation Biosciences director Jennifer Carver reported an equity award of 41,981 shares of common stock on January 8, 2026. The filing shows these were granted at a stated price of $0.90 per share and are identified in a footnote as restricted stock units issued under the company’s 2021 Equity Incentive Plan. The award vests quarterly over one year from the grant date, meaning portions of the grant will settle into shares over four installments.

After this grant, Carver beneficially owns 57,669 shares of Revelation Biosciences common stock, all held directly. The filing reflects her status as a director of the company and indicates the transaction was reported by a single reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARVER JENNIFER

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								15,688	D
Common Stock(1)	01/08/2026		A		41,981	A	$0.9	57,669	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

	/s/ J.P. Galda, as attorney-in-fact for Jennifer Carver	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Revelation Biosciences (REVB) report for Jennifer Carver?

The company reported that director Jennifer Carver received an equity award of 41,981 shares of common stock on January 8, 2026, recorded as an acquisition transaction.

At what price were Jennifer Carver’s Revelation Biosciences shares recorded in the grant?

The grant was recorded at a stated price of $0.90 per share for the 41,981 shares of common stock reported in the transaction.

How many Revelation Biosciences shares does Jennifer Carver own after this transaction?

Following the reported grant, Jennifer Carver beneficially owns 57,669 shares of Revelation Biosciences common stock, all listed as held directly.

What type of equity award did Jennifer Carver receive from Revelation Biosciences (REVB)?

A footnote describes the award as a Restricted Stock Unit granted under the company’s 2021 Equity Incentive Plan, tied to Revelation Biosciences common stock.

How do Jennifer Carver’s restricted stock units in Revelation Biosciences vest?

The restricted stock units vest quarterly over one year from the grant date, meaning they vest in four installments during the year following January 8, 2026.

What is Jennifer Carver’s relationship to Revelation Biosciences?

The filing identifies Jennifer Carver as a director of Revelation Biosciences, Inc. and indicates the form was filed by one reporting person.